Gilead Sciences

Medicare would cover CAR-T cell therapies under new CMS proposal
Medicare would cover CAR-T cell therapies under new CMS proposal
Marketwatch
Medicare
CAR-T
cell therapy
CMS
Novartis
Kymriah
Gilead Sciences
Yescarta
Flag link:
It's a flop: Gilead's top late-stage drug selonsertib flunked its first Phase III NASH trial
It's a flop: Gilead's top late-stage drug selonsertib flunked its first Phase III NASH trial
Endpoints
Gilead Sciences
NASH
selonsertib
clinical trials
Flag link:
Pharma companies clear the R&D decks in Q4
Pharma companies clear the R&D decks in Q4
Pharmaforum
R&D
GSK
Sanofi
Eli Lilly
Roche
Gilead Sciences
Flag link:
Why Gilead Sciences Stock Perked Up in January
Why Gilead Sciences Stock Perked Up in January
Motley Fool
Gilead Sciences
JPMHC 2019
Flag link:
Trump's HIV pledge comes as Gilead pumps cash into Truvada for PrEP
Trump's HIV pledge comes as Gilead pumps cash into Truvada for PrEP
Fierce Pharma
Gilead Sciences
HIV
Descovy
PrEP
Donald Trump
Flag link:
Gilead drops anti-BCMA CAR-T from Kite, takes $820M charge
Gilead drops anti-BCMA CAR-T from Kite, takes $820M charge
Fierce Biotech
Gilead Sciences
Multiple Myeloma
Kite Pharma
anti-BCMA
Flag link:
Gilead executives predict patience—and some deal scouting—from new CEO Daniel O'Day
Gilead executives predict patience—and some deal scouting—from new CEO Daniel O'Day
Fierce Pharma
Gilead Sciences
Daniel O'Day
M&A
Pharma CEOs
Flag link:
Gilead Misses Mark on Earnings as Daniel O'Day Prepares to Take Helm
Gilead Misses Mark on Earnings as Daniel O'Day Prepares to Take Helm
Bloomberg
Gilead Sciences
earnings
Flag link:
Gilead's hepatitis C generics are on their way, but Epclusa's getting TV ads anyway
Gilead's hepatitis C generics are on their way, but Epclusa's getting TV ads anyway
Fierce Pharma
Gilead Sciences
hepatitis C
Epclusa
drug ads
television ads
Flag link:
Novartis changes NICE's mind on Kymriah, giving CAR-T rival Gilead some company
Novartis changes NICE's mind on Kymriah, giving CAR-T rival Gilead some company
Fierce Pharma
Novartis
Kymriah
CAR-T
UK
diffuse large B-cell lymphoma
Gilead Sciences
Flag link:
Based On Sales Forecasts For 2018 FDA Approved Drugs, Big Pharma Not Just Focused On Blockbusters
Based On Sales Forecasts For 2018 FDA Approved Drugs, Big Pharma Not Just Focused On Blockbusters
Forbes
Big Pharma
Pfizer
Merck
AstraZeneca
Gilead Sciences
Alexion
Vertex Pharmaceuticals
Flag link:
What’s up with all the buzz about Gilead’s PhIII NASH drug selonsertib?
What’s up with all the buzz about Gilead’s PhIII NASH drug selonsertib?
Endpoints
clinical trials
NASH
Gilead Sciences
selonsertib
Flag link:
Is the Smoldering NASH Market Ready to Burst Into Flames?
Is the Smoldering NASH Market Ready to Burst Into Flames?
BioSpace
NASH
Allergan
Regeneron
Alnylam
AstraZeneca
Merck
Takeda
Gilead Sciences
Bristol-Myers Squibb
Intercept Pharmaceuticals
Flag link:
Gilead, Genentech join PhRMA
Gilead, Genentech join PhRMA
BioCentury
PhRMA
Genentech
Gilead Sciences
Flag link:
NASH Space in Focus in 2019 as Firms Look to Diversify
NASH Space in Focus in 2019 as Firms Look to Diversify
Yahoo/Zacks.com
NASH
Gilead Sciences
Merck
Roche
Novartis
Jecure Therapeutics
Pfizer
Celgene
Eli Lilly
Flag link:
Day One of JPM Brings Excitement and Promise for a New Year in Biotech and Pharma
Day One of JPM Brings Excitement and Promise for a New Year in Biotech and Pharma
BioSpace
JPMHC 2019
M&A
Eli Lilly
Loxo Oncology
SAGE Therapeutics
Sanofi
Regeneron
Bristol-Myers Squibb
Celgene
Novartis
Gilead Sciences
Flag link:
7 Things to Expect for Gilead Sciences in 2019
7 Things to Expect for Gilead Sciences in 2019
Motley Fool
Gilead Sciences
JPMHC 2019
HIV
hepatitis C
M&A
Daniel O'Day
Flag link:
Gilead Inks $785 Million Deal With Yuhan for NASH Development
Gilead Inks $785 Million Deal With Yuhan for NASH Development
BioSpace
Gilead Sciences
NASH
South Korea
Yuhan
Flag link:
Could Gilead, Amgen and AbbVie follow Bristol-Myers into megadeal territory?
Could Gilead, Amgen and AbbVie follow Bristol-Myers into megadeal territory?
Fierce Pharma
M&A
Bristol-Myers Squibb
Celgene
Gilead Sciences
AbbVie
Amgen
Flag link:
Six Things to Watch for at the JP Morgan Healthcare Conference
Six Things to Watch for at the JP Morgan Healthcare Conference
BioSpace
Moderna Therapeutics
Sarepta Therapeutics
Biogen
Gilead Sciences
Bluebird Bio
Flag link:

Pages